Immunobiologicals in Psoriasis at HUOL, UFRN, Natal, RN

Psoriasis is a chronic, immune-mediated, multifactorial inflammatory disease that may be associated with comorbidities and interfere with quality of life. The patients included in the study were treated with immunobiological agents from March 2008 to March 2015. Of the patients studied, 17 started treatment with Adalimumab, 15 with Infliximab, and 5 with Etanercept. The results showed that 37 patients (60.7%) controlled their psoriasis with a single immunobiological agent; 15 patients (24.6%) with a second immunobiological agent; 6 patients (9.8%) with a third immunobiological agent; and only 3 patients (4.9%) needed to use a fourth immunobiological agent, Ustekinumab, to achieve an effective therapeutic response. Immunobiologicals represent an important therapeutic resource for severe forms of psoriasis. In conclusion, excellent therapeutic results were observed in all patients, with few adverse effects and a high rate of adherence to treatment, providing them with personal rehabilitation and family, social, and professional reintegration.

Autorentext
Associate Professor of Dermatology at the Federal University of Rio Grande do Norte PhD in Health Sciences from the Federal University of Rio Grande do Norte Master's Degree in Dermatology from the Federal University of Minas Gerais Specialist in Dermatology from the Brazilian Society of Dermatology Medical Residency in Dermatology IASERJ, RJ